JP Morgan Chase
BBIO icon

JP Morgan Chase’s BridgeBio Pharma BBIO Stock Holding History

JP Morgan Chase’s Portfolio BBIO Stock Details BBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$173M Buy
2,397,995
+1,085,736
+83% +$76M 0.01% 804
2026
Q1 		$91M Buy
1,312,259
+453,291
+53% +$32.9M 0.01% 1041
2025
Q4 		$65.7M Buy
858,968
+564,852
+192% +$37.1M ﹤0.01% 1189
2025
Q3 		$15.3M Sell
294,116
-180,137
-38% -$8.79M ﹤0.01% 2325
2025
Q2 		$20.5M Buy
474,253
+299,203
+171% +$10.9M ﹤0.01% 1939
2025
Q1 		$6.05M Sell
175,050
-124,164
-41% -$4.19M ﹤0.01% 2990
2024
Q4 		$8.21M Sell
299,214
-916,902
-75% -$23.7M ﹤0.01% 2882
2024
Q3 		$31M Buy
1,216,116
+1,040,037
+591% +$27.3M ﹤0.01% 1649
2024
Q2 		$4.46M Sell
176,079
-190,574
-52% -$5.21M ﹤0.01% 3114
2024
Q1 		$11.3M Buy
366,653
+146,734
+67% +$4.99M ﹤0.01% 2368
2023
Q4 		$8.88M Buy
219,919
+5,850
+3% +$176K ﹤0.01% 2595
2023
Q3 		$5.64M Sell
214,069
-12,068
-5% -$342K ﹤0.01% 2737
2023
Q2 		$3.89M Sell
226,137
-110,231
-33% -$1.66M ﹤0.01% 3073
2023
Q1 		$5.58M Sell
336,368
-192,757
-36% -$2.25M ﹤0.01% 2728
2022
Q4 		$4.03M Buy
529,125
+238,841
+82% +$2.29M ﹤0.01% 3006
2022
Q3 		$2.88M Sell
290,284
-93,796
-24% -$975K ﹤0.01% 3172
2022
Q2 		$3.49M Sell
384,080
-364,026
-49% -$3.04M ﹤0.01% 3094
2022
Q1 		$7.59M Sell
748,106
-794,597
-52% -$8.15M ﹤0.01% 2637
2021
Q4 		$25.7M Buy
1,542,703
+88,515
+6% +$3.74M ﹤0.01% 1609
2021
Q3 		$68.2M Sell
1,454,188
-158,767
-10% -$8.51M 0.01% 1034
2021
Q2 		$98.3M Buy
1,612,955
+152,406
+10% +$8.7M 0.01% 907
2021
Q1 		$90M Buy
1,460,549
+106,130
+8% +$6.94M 0.01% 899
2020
Q4 		$96.3M Buy
1,354,419
+51,111
+4% +$2.47M 0.01% 784
2020
Q3 		$48.4M Buy
1,303,308
+278,834
+27% +$8.77M 0.01% 991
2020
Q2 		$33.4M Buy
1,024,474
+101,818
+11% +$3.1M 0.01% 1068
2020
Q1 		$26.8M Buy
922,656
+330,004
+56% +$10.2M 0.01% 1083
2019
Q4 		$20.8M Buy
592,652
+3,755
+0.6% +$104K ﹤0.01% 1568
2019
Q3 		$12.6M Sell
588,897
-328,526
-36% -$9.09M ﹤0.01% 1948
2019
Q2 		$25.3M Buy
+917,423
New +$25M ﹤0.01% 1395

Other funds holding BBIO

JT
Jupiter Topco New York $245B AUM
KKRC
Kohlberg Kravis Roberts & Co New York $5.71B AUM 72.37% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
ACM
Aisling Capital Management New York $472M AUM 106.83% 1-Year Est. Return

JP Morgan Chase's BBIO Position: Q2 2026 in Review

JP Morgan Chase increased its BridgeBio Pharma (BBIO) stake by 83% in Q2 2026, buying an estimated $76M and bringing the position to 2,397,995 shares worth $173M. The position accounts for 0.01% of the portfolio, ranked #804.

JP Morgan Chase first reported a position in BBIO in Q2 2019 and has held it in 29 quarters since. 474 funds tracked by Wall St. Rank hold BBIO as of Q2 2026.

  • JP Morgan Chase held 2,397,995 shares of BridgeBio Pharma worth $173M as of Q2 2026.
  • JP Morgan Chase bought 1,085,736 BridgeBio Pharma shares in Q2 2026, an estimated $76M.
  • BridgeBio Pharma made up 0.01% of JP Morgan Chase's portfolio in Q2 2026, its #804 holding.
  • JP Morgan Chase first reported a position in BridgeBio Pharma in Q2 2019 and has held it in 29 quarters since.
  • 474 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q2 2026.

Based on JP Morgan Chase's 13F filing for Q2 2026, filed 12 Aug 2026.